IL287213A - Methods for treating patients with psoriatic arthritis - Google Patents

Methods for treating patients with psoriatic arthritis

Info

Publication number
IL287213A
IL287213A IL287213A IL28721321A IL287213A IL 287213 A IL287213 A IL 287213A IL 287213 A IL287213 A IL 287213A IL 28721321 A IL28721321 A IL 28721321A IL 287213 A IL287213 A IL 287213A
Authority
IL
Israel
Prior art keywords
subjects
treatment
methods
psoriatic arthritis
psoriatic
Prior art date
Application number
IL287213A
Other languages
English (en)
Hebrew (he)
Inventor
Kirti Wardhaman Ganorkar
Atul Mathuradas Raut
Anil Raghavan
Siu-Long Yao
Original Assignee
Sun Pharma Global Fze
Kirti Wardhaman Ganorkar
Atul Mathuradas Raut
Anil Raghavan
Yao Siu Long
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72837755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL287213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharma Global Fze, Kirti Wardhaman Ganorkar, Atul Mathuradas Raut, Anil Raghavan, Yao Siu Long filed Critical Sun Pharma Global Fze
Publication of IL287213A publication Critical patent/IL287213A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL287213A 2019-04-15 2021-10-12 Methods for treating patients with psoriatic arthritis IL287213A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Publications (1)

Publication Number Publication Date
IL287213A true IL287213A (en) 2021-12-01

Family

ID=72837755

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287213A IL287213A (en) 2019-04-15 2021-10-12 Methods for treating patients with psoriatic arthritis

Country Status (16)

Country Link
US (1) US20220298233A1 (cg-RX-API-DMAC10.html)
EP (1) EP3956357A4 (cg-RX-API-DMAC10.html)
JP (2) JP7628962B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210140780A (cg-RX-API-DMAC10.html)
CN (1) CN113825768A (cg-RX-API-DMAC10.html)
AU (1) AU2020259375A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021020612A2 (cg-RX-API-DMAC10.html)
CA (1) CA3143604A1 (cg-RX-API-DMAC10.html)
IL (1) IL287213A (cg-RX-API-DMAC10.html)
JO (1) JOP20210279A1 (cg-RX-API-DMAC10.html)
MA (1) MA55729A (cg-RX-API-DMAC10.html)
MX (1) MX2021012652A (cg-RX-API-DMAC10.html)
MY (1) MY210310A (cg-RX-API-DMAC10.html)
PH (1) PH12021552536A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202111056YA (cg-RX-API-DMAC10.html)
WO (1) WO2020212874A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025036280A1 (zh) * 2023-08-11 2025-02-20 信达生物制药(苏州)有限公司 既往接受生物制剂治疗斑块状银屑病的受试者转用抗IL23p19抗体治疗斑块状银屑病的方法
TW202511290A (zh) * 2023-09-07 2025-03-16 大陸商信達生物製藥（蘇州）有限公司 一種重組抗ＩＬ－２３ｐ１９抗體治療中重度銀屑病的方法
WO2026069253A1 (en) * 2024-09-30 2026-04-02 Sun Pharmaceutical Industries Limited Long term safety of tildrakizumab in psoriatic arthritis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
HUE042172T2 (hu) * 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
KR102049223B1 (ko) * 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항－ｉｌ－２３ 항체
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19

Also Published As

Publication number Publication date
AU2020259375A1 (en) 2021-10-28
MX2021012652A (es) 2022-01-24
EP3956357A4 (en) 2023-01-04
MY210310A (en) 2025-09-10
JP7628962B2 (ja) 2025-02-12
EP3956357A1 (en) 2022-02-23
SG11202111056YA (en) 2021-11-29
CN113825768A (zh) 2021-12-21
US20220298233A1 (en) 2022-09-22
BR112021020612A2 (pt) 2021-12-28
PH12021552536A1 (en) 2022-07-04
MA55729A (fr) 2022-02-23
JOP20210279A1 (ar) 2021-10-14
WO2020212874A1 (en) 2020-10-22
KR20210140780A (ko) 2021-11-23
JP2022529266A (ja) 2022-06-20
JP2025069284A (ja) 2025-04-30
CA3143604A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
ZA202100528B (en) Acid gas treatment
SG11202104222TA (en) Method of treatment of biological surfaces
IL283948A (en) Methods for treating depression
SG11202108757XA (en) Methods for treating muscular dystrophy with casimersen
IL286000A (en) Asketamine for the treatment of depression
IL290983A (en) Treatment methods
IL284791A (en) Disease treatment methods with MAGL inhibitors
EP3956357A4 (en) METHODS OF TREATMENT OF SUBJECTS WITH PSORIAL ARTHRITIS
GB201808575D0 (en) Methods for the treatment of psoriatic arthrits
IL281480B (en) Process and device for treating organic matter
HUE067201T2 (hu) Eljárás és intermedier oxetan-2-il-metánamin elõállítására
GB202015959D0 (en) Treatment of diseases involving NAD
IL290770A (en) Compounds and methods for treating oxalate-related diseases
HUE049463T2 (hu) Eljárás kavicsok kezelésére
IL282293A (en) Treatment methods with mixed metal compounds
GB201918853D0 (en) Methods of treatment
PL3292226T3 (pl) Sposób obróbki szlamu zawierającego żelazo
ZA202001536B (en) Method for the treatment of wastewaters
IL269681A (en) New methods for treating multiple sclerosis
HUP1800109A2 (en) Process and equipment for the treatment of biomass
IL286099A (en) Methods of treating disease with levoketoconazole
HK40067726A (en) Methods for treatment of subjects with psoriatic arthritis
GB201911056D0 (en) Treatment of ADD/ADHD
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
ZA202001642B (en) Method for the treatment of iron-containing sludge